MDxHealth SA (MDXH) FinancialsMDXHMDxHealth SA

Evaluating the bottom line, MDxHealth SA maintains a gross margin of 59.79%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -12.78%, while the net margin is -32.58%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively MDXH converts its operational activities into shareholder value.

In the context of the broader market, MDXH competes directly with industry leaders such as DRIO and NNOX. With a market capitalization of $77.10M, it holds a leading position in the sector. When comparing efficiency, MDXH's gross margin of 59.79% stands against DRIO's 61.66% and NNOX's -60.03%. Such benchmarking helps identify whether MDxHealth SA is trading at a premium or discount relative to its financial performance.

MDxHealth reported Q2 2026 revenue of $27.2 million, a 16% increase from the previous year, but the adjusted EBITDA remains negative at -$2.3 million, indicating ongoing operational challenges despite revenue growth.